DOCSLIB.ORG

Anti-Doping Convention

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Doping Convention European Treaty Series - No. 135 Anti-Doping Convention Strasbourg, 16.XI.1989 Appendix – AMENDMENTS TO THE APPENDIX (approved by the Monitoring Group under Article 11.1.b of the Convention at its 47th meeting) (Strasbourg, 4 November 2017) THE 2018 PROHIBITED LIST - WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE : 1 JANUARY 2018 SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S.4.4, S.4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES Bolandiol (estr-4-ene-3β,17β-diol ); S0. NON-APPROVED SUBSTANCES Bolasterone; Calusterone; Any pharmacological substance which is not Clostebol; addressed by any of the subsequent sections of Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en- the List and with no current approval by any 20-yn-17α-ol); governmental regulatory health authority for Dehydrochlormethyltestosterone (4-chloro- human therapeutic use (e.g drugs under pre- 17β-hydroxy-17α-methylandrosta-1,4-dien-3- clinical or clinical development or discontinued, one); designer drugs, substances approved only for Desoxymethyltestosterone (17α-methyl-5α- veterinary use) is prohibited at all times. androst-2-en-17β-ol); Drostanolone; S1. ANABOLIC AGENTS Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Anabolic agents are prohibited. Formebolone; …………………………………………………… Furazabol (17α-methyl 1. ANABOLIC ANDROGENIC STEROIDS [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan- (AAS) 17β-ol); * Gestrinone; a. Exogenous AAS, including: Mestanolone; Mesterolone; 1-Androstenediol (5α-androst-1-ene-3β,17β- Metandienone (17β-hydroxy-17α- diol); methylandrosta-1,4-dien-3-one); 1-Androstenedione (5α-androst-1-ene-3,17- Metenolone; dione); Methandriol; 1-Androsterone (3α-hydroxy-5α-androst-1- Methasterone (17β-hydroxy-2α,17α-dimethyl- ene-17-one); 5α-androstan-3-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en- Methyldienolone (17β-hydroxy-17α- 3-one); methylestra-4,9-dien-3-one); 4-Hydroxytestosterone (4,17β- Methyl-1-testosterone (17β-hydroxy-17α- dihydroxyandrost-4-en-3-one); methyl-5α-androst-1-en-3-one); ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2018 Prohibited List __________________________________________________________________________________ Methylnortestosterone (17β-hydroxy-17α- b. Endogenous** AAS when administered methylestr-4-en-3-one); exogenously: Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy- 19-Norandrostenediol (estr-4-ene-3,17-diol); 17α-methylestra-4,9,11-trien-3-one); 19-Norandrostenedione (estr-4-ene-3,17- Mibolerone; dione); Norboletone; Androstanolone (5α-dihydrotestosterone, Norclostebol; 17β-hydroxy-5α-androstan-3-one); Norethandrolone; Androstenediol (androst-5-ene-3β,17β-diol); Oxabolone; Androstenedione (androst-4-ene-3,17-dione); Oxandrolone; Boldenone; Boldione (androsta-1,4-diene- Oxymesterone; 3,17-dione); Oxymetholone; Nandrolone (19-nortestosterone); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]- Prasterone (dehydroepiandrosterone, DHEA, 1'H-pyrazolo[3,4:2,3]-5α-androstane); 3β-hydroxyandrost-5-en-17-one); Quinbolone; Testosterone; Stanozolol; Stenbolone; and their metabolites and isomers, including Tetrahydrogestrinone (17-hydroxy-18a-homo- but not limited to: 19-nor-17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3- 3β-Hydroxy-5α-androstan-17-one; one); 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; and other substances with a similar chemical 5α-Androstane-3α,17β-diol; structure or similar biological effect(s). 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β,17β-diol); 5-Androstenedione (androst-5-ene-3,17- dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2 ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2018 Prohibited List __________________________________________________________________________________ ……………………………………………………. 2. OTHER ANABOLIC AGENTS 2. Peptide hormones and Hormone Modulators, Including but not limited to: 2.1 Chorionic Gonadotrophin (CG) and Clenbuterol, selective androgen receptor Luteinizing Hormone (LH) and their modulators (SARMs, e.g. andarine, LGD-4033, releasing factors, e.g. Buserelin, ostarine and RAD140), tibolone, zeranol and deslorelin, gonadorelin, goserelin, zilpaterol. leuprorelin, nafarelin and triptorelin, in males; For purposes of this section: * “exogenous” refers to a substance which is not 2.2 Corticotrophins and their releasing ordinarily produced by the body naturally. factors, e.g Corticorelin. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. 2.3 Growth Hormone (GH) its fragments and releasing factors, including, but not limited to: S2. PEPTIDE HORMONES, GROWTH Growth Hormone fragments, e.g. FACTORS, RELATED SUBSTANCES, AOD-9604 and hGH 176-191; AND MIMETICS Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. The following substances, and other CJC-1293, CJC-1295, sermorelin and substances with similar chemical structure or tesamorelin; similar biological effect(s), are prohibited: Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin 1. Erythropoietins (EPO) and agents affecting mimetics, e.g. erythropoiesis, including, but not limited to: anamorelin, ipamorelin and tabimorelin; 1.1 Erythropoietin-Receptor Agonists,e.g. GH-Releasing Peptides (GHRPs), e.g. Darbepoietin (dEPO); alexamorelin, GHRP-1, GHRP-2 Erythropoietins (EPO); (pralmorelin), GHRP-3, GHRP-4, EPO based constructs [EPO-Fc, GHRP-5, GHRP-6, and hexarelin. methoxy polyethylene glycol-epoetin beta (CERA)]; 3. Growth Factors and Growth Factor EPO-mimetic agents and their Modulators, including but not limited to: constructs (e.g. CNTO 530, Fibroblast Growth Factors (FGFs); peginesatide). Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its 1.2 Hypoxia-inducible factor (HIF) analogues; activating agents, e.g. Mechano Growth Factors (MGFs); Argon; Platelet-Derived Growth Factor (PDGF); Cobalt; Thymosin-β4 and its derivatives e.g. TB- Molidustat; 500; Roxadustat (FG-4592); Vascular-Endothelial Growth Factor Xenon. (VEGF). 1.3 GATA inhibitors, e.g. Additional growth factors or growth factors K-11706. modulators affecting muscle, tendon or ligament protein synthesis/degradation, 1.4 TGF-beta (TGF-β) inhibitors, e.g. vascularisation, energy utilisation, regenerative Luspatercept; capacity or fibre type switching. Sotatercept. 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamulated EPO (CEPO). 3 S3. BETA-2 AGONISTS S4. HORMONE AND METABOLIC MODULATORS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. The following hormone and metabolic modulators are prohibited: Including, but not limited to: 1. Aromatase inhibitors including, but not Fenoterol; limited to: Formoterol, 4-Androstene-3,6,17 trione (6-oxo); Higenamine; Aminoglutethimide; Indacaterol; Anastrozole; Androsta-1,4,6-triene-3,17- Olodaterol; dione (androstatrienedione); Procaterol; Androsta-3,5-diene-7,17-dione Reproterol; (arimistane); Exemestane; Salbutamol; Formestane; Salmeterol; Letrozole; Terbutaline; Testolactone. Tulobuterol; Vilanterol. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Except: Raloxifene; Inhaled salbutamol: maximum Tamoxifen; 1600 micrograms over 24 hours in divided Toremifene. doses not to exceed 800 micrograms over 12 hours starting from any dose; 3. Other anti-estrogenic substances including, Inhaled formoterol: maximum delivered but not limited to: dose 54 micrograms over 24 hours; Clomiphene; Inhaled salmeterol: maximum Cyclofenil; 200 micrograms over 24 hours. Fulvestrant. The presence in urine of salbutamol in excess 4. Agents modifying myostatin function(s) of 1000 ng/mL or formoterol in excess of including, but not limited, to: myostatin 40 ng/mL is not consistent with therapeutic use inhibitors. of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the 5. Metabolic modulators: Athlete proves, through a controlled pharmacokinetic study, that the abnormal 5.1 Activators of the AMP-activated result was the consequence of the use of a protein kinase (AMPK), e.g. AICAR, therapeutic dose (by inhalation) up to the SR9009; maximum dose indicated above. and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2- (2-methyl-4-((4-methyl-2-(4- (trifluoromethyl)phenyl)thiazol-5- yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2018 Prohibited List __________________________________________________________________________________ S5. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide;
Load more

Recommended publications
  • The 2006 Prohibited List International Standard
    The World Anti-Doping Code THE 2006 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2006. THE 2006 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2006 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α- dimethyl-5α-androstane-3-one-17β-ol); methyldienolone
    [Show full text]
  • 5 Part 1300—Definitions
    PART 1300—DEFINITIONS (7) 5-androstenediol (3b,17b-dihydroxy- androst-5-ene) Sec. (8) 1-androstenedione ([5a]-androst-1- 1300.01 Definitions relating to controlled en-3,17-dione) substances. (9) 4-androstenedione (androst-4-en- 1300.02 Definitions relating to listed chemi- 3,17-dione) cals. (10) 5-androstenedione (androst-5-en- 1300.03 Definitions relating to electronic or- 3,17-dione) ders for controlled substances and elec- tronic prescriptions for controlled sub- (11) bolasterone (7a,17a-dimethyl-17b- stances. hydroxyandrost-4-en-3-one) 1300.04 Definitions relating to the dis- (12) boldenone (17b-hydroxyandrost-1,4- pensing of controlled substances by diene-3-one) means of the Internet. (13) boldione (androsta-1,4-diene-3,17- 1300.05 Definitions relating to the disposal dione) of controlled substances. (14) calusterone (7b,17a-dimethyl-17b- AUTHORITY: 21 U.S.C. 802, 821, 822, 829, hydroxyandrost-4-en-3-one) 871(b), 951, 958(f). (15) clostebol (4-chloro-17b- SOURCE: 62 FR 13941, Mar. 24, 1997, unless hydroxyandrost-4-en-3-one) otherwise noted. (16) dehydrochloromethyltestosterone (4-chloro-17b-hydroxy-17a-methyl- § 1300.01 Definitions relating to con- androst-1,4-dien-3-one) trolled substances. (17) desoxymethyltestosterone (17a- (a) Any term not defined in this part methyl-5a-androst-2-en-17b-ol) shall have the definition set forth in (a.k.a. ‘madol‘) section 102 of the Act (21 U.S.C. 802), (18) D1-dihydrotestosterone (a.k.a.‘1- except that certain terms used in part testosterone‘) (17b-hydroxy-5a- 1316 of this chapter are defined at the androst-1-en-3-one) beginning of each subpart of that part.
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • 2010 Prohibited List
    The World Anti-Doping Code THE 2010 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2010 The Prohibited List 2010 19 September 2009 THE 2010 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2010 All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone
    [Show full text]
  • Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012 Arrangement
    Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012 Arrangement MISUSE OF DRUGS (MISCELLANEOUS AMENDMENTS) (No. 2) (JERSEY) ORDER 2012 Arrangement Article 1 Schedule 2 to the Misuse of Drugs (Jersey) Law 1978 amended .................... 3 2 Schedule to the Misuse of Drugs (Designation) (Jersey) Order 1989 amended .......................................................................................................... 9 3 Misuse of Drugs (General Provisions) (Jersey) Order 2009 amended .......... 11 4 Citation and commencement ......................................................................... 18 ◊ Page - 1 Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012 Article 1 MISUSE OF DRUGS (MISCELLANEOUS AMENDMENTS) (No. 2) (JERSEY) ORDER 2012 Made Coming into force THE MINISTER FOR HEALTH AND SOCIAL SERVICES, in pursuance of Articles 3, 4, 5, 8, 12, 13 and 27 of the Misuse of Drugs (Jersey) Law 1978, and after consultation with the Advisory Council on the Misuse of Drugs, orders as follows – 1 Schedule 2 to the Misuse of Drugs (Jersey) Law 1978 amended (1) In this Article “Law” means the Misuse of Drugs (Jersey) Law 1978. (2) In Part 1 of Schedule 2 to the Law, in paragraph 1(a), after the entry “Sufentanil” there shall be inserted the following entry – “Tapentadol”. (3) In Part 2 of Schedule 2 to the Law – (a) in paragraph 1(a) after the entry “Methylphenobarbitone” there shall be inserted the entry – “Nabilone”; (b) for the full stop at the end of paragraph 1(i) there shall be substituted a semi-colon; and (c) after paragraph 1(i) there shall be added the following sub- paragraphs – “(j) the following substances – 6-(2-aminopropyl)benzofuran 5-(2-aminopropyl)benzofuran; (k) Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say – ◊ Page - 3 Misuse of Drugs (Miscellaneous Amendments) (No.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]